Gujarat Themis Biosyn Limited

6%

es, wherein new molecules are being developed. Our R&D spend during this quarter was approximately 6% of our revenue. The additional fermentation capacity that we are building is also well underway in

Rs. 35.9 crore

o be completed by the end of this calendar year. In Q1 FY26, our top line, EBITDA and PAT stood at Rs. 35.9 crores, Rs. 13.9 crores, and Rs. 9.1 crores, respectively. EBITDA and PAT are impacted momentarily due t

Rs. 13.9 crore

the end of this calendar year. In Q1 FY26, our top line, EBITDA and PAT stood at Rs. 35.9 crores, Rs. 13.9 crores, and Rs. 9.1 crores, respectively. EBITDA and PAT are impacted momentarily due to one-time impact

Rs. 9.1 crore

ndar year. In Q1 FY26, our top line, EBITDA and PAT stood at Rs. 35.9 crores, Rs. 13.9 crores, and Rs. 9.1 crores, respectively. EBITDA and PAT are impacted momentarily due to one-time impact from legal expenses

Rs. 0.83

mpact from legal expenses and GST. The EPS (for each share of face value Re. 1) for the quarter is Rs. 0.83.” 3 Click to edit Master title style Quarterly Financial Highlights Revenue (Rs. Cr) 38.8 34.

47.8%

FY24-25 Q1 FY25-26 EBITDA (Rs. Cr) / Margin (%) PAT (Rs. Cr) / Margin (%) 25 20 15 10 5 0 47.8% 44.3% 47.7% 42.5% 38.8% 18.6 15.4 18.9 16.0 13.9 Q1 FY24-25 Q2 FY24-25 Q3 FY24-25 Q4 FY24

44.3%

Q1 FY25-26 EBITDA (Rs. Cr) / Margin (%) PAT (Rs. Cr) / Margin (%) 25 20 15 10 5 0 47.8% 44.3% 47.7% 42.5% 38.8% 18.6 15.4 18.9 16.0 13.9 Q1 FY24-25 Q2 FY24-25 Q3 FY24-25 Q4 FY24-25 Q1

47.7%

25-26 EBITDA (Rs. Cr) / Margin (%) PAT (Rs. Cr) / Margin (%) 25 20 15 10 5 0 47.8% 44.3% 47.7% 42.5% 38.8% 18.6 15.4 18.9 16.0 13.9 Q1 FY24-25 Q2 FY24-25 Q3 FY24-25 Q4 FY24-25 Q1 FY25-26

42.5%

EBITDA (Rs. Cr) / Margin (%) PAT (Rs. Cr) / Margin (%) 25 20 15 10 5 0 47.8% 44.3% 47.7% 42.5% 38.8% 18.6 15.4 18.9 16.0 13.9 Q1 FY24-25 Q2 FY24-25 Q3 FY24-25 Q4 FY24-25 Q1 FY25-26 60%

38.8%

(Rs. Cr) / Margin (%) PAT (Rs. Cr) / Margin (%) 25 20 15 10 5 0 47.8% 44.3% 47.7% 42.5% 38.8% 18.6 15.4 18.9 16.0 13.9 Q1 FY24-25 Q2 FY24-25 Q3 FY24-25 Q4 FY24-25 Q1 FY25-26 60% 50% 40

60%

42.5% 38.8% 18.6 15.4 18.9 16.0 13.9 Q1 FY24-25 Q2 FY24-25 Q3 FY24-25 Q4 FY24-25 Q1 FY25-26 60% 50% 40% 30% 20% 10% 0% 14 12 10 8 6 4 2 0 34.1% 30.4% 32.8% 31.8% 13.2 10.6 13

50%

38.8% 18.6 15.4 18.9 16.0 13.9 Q1 FY24-25 Q2 FY24-25 Q3 FY24-25 Q4 FY24-25 Q1 FY25-26 60% 50% 40% 30% 20% 10% 0% 14 12 10 8 6 4 2 0 34.1% 30.4% 32.8% 31.8% 13.2 10.6 13.0 1

“No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.”

“Herein we shall be offering synthetic as well as fermentation-based APIs and will target export markets such as the US and Europe.”

“In Q1 FY26, our top line, EBITDA and PAT stood at Rs.”

“Cr) 38.8 34.7 39.5 37.7 35.9 Q1 FY24-25 Q2 FY24-25 Q3 FY24-25 Q4 FY24-25 Q1 FY25-26 EBITDA (Rs.”

“Cr) / Margin (%) 25 20 15 10 5 0 47.8% 44.3% 47.7% 42.5% 38.8% 18.6 15.4 18.9 16.0 13.9 Q1 FY24-25 Q2 FY24-25 Q3 FY24-25 Q4 FY24-25 Q1 FY25-26 60% 50% 40% 30% 20% 10% 0% 14 12 10 8 6 4 2 0 34.1% 30.4% 32.8% 31.8% 13.2 10.6 13.0 12.0 25.2% 9.1 40% 35% 30% 25% 20% 15% 10% 5% 0% Q1 FY24-25 Q2 FY24-25 Q3 FY24-25 Q4 FY24-25 Q1 FY25-26 4 Click to edit Master title style Q1 FY25-26 Financial Highlights Rs.”

Sub

1

Investor Relations Advisors

1

Sub

Investor Presentation In terms of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), we submit herewith the Investors’ Presentation of the Gujarat Themis Biosyn Limited (‘the Company’) with respect to Company’s Business Overview. Further, a copy of the same is also available on the website of the Company, viz., http://www.gtbl.in/ Kindly take the same on record and acknowledge receipt of the same. Thanking you, Yours faithfully, For Gujarat Themis Biosyn Limited Vineet Gawankar Company Secretary and Compliance Officer MUMBAI OFFICE: Themis House, 11/12 Udyog Nagar, S.V Road, Goregaon (West), Mumbai – 400 104 Tel: 91-22-67607080 / 28757836 Fax: 28746621 / 67607019; E-mail: gtblmumbai@gtbl.in Website Address: www.gtbl.in Gujarat Themis Biosyn Limited Investor Presentation Q1 FY2025-26 Click to edit Master title style Disclaimer This presentation has been prepared by Gujarat Themis Biosyn Limited (the “Company” or “GTBL”) solely for

Investor Relations Advisors

Gujarat Themis Biosyn Limited Adfactors PR Pvt. Ltd. Mr. Pradeep Chandan pradeep.chandan@themismedicare.com Mr. Rahul Trivedi Mr. Amit Sharma rahul.trivedi@adfactorspr.com amit.sharma@adfactorspr.com www.gtbl.in www.adfactorspr.com 15